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Abstract
Background: Gastrointestinal harm, known to occur with NSAIDs, is thought to be lower with NSAID
and gastroprotective agent, and with inhibitors selective to cyclooxygenase-2 (coxibs) at usual plasma
concentrations. We examine competing strategies for available evidence of reduced gastrointestinal
bleeding in clinical trials and combine this evidence with evidence from clinical practice on whether the
strategies work in the real world, whether guidance on appropriate prescribing is followed, and whether
patients adhere to the strategies.
Methods: We used a series of systematic literature searches to find full publications of relevant studies
for evidence about the efficacy of these different gastroprotection strategies in clinical trials, and for
evidence that they worked and were adhered to in clinical practice – whether they were effective. We
chose to use good quality systematic reviews and meta-analyses when they were available.
Results: Evidence of efficacy of coxibs compared to NSAIDs for upper gastrointestinal bleeding was
strong, with consistent reductions in events of about 50% in large randomised trials (34,460 patients),
meta-analyses of randomised trials (52,474 patients), and large observational studies in clinical practice
(3,093 bleeding events). Evidence on the efficacy of NSAID plus gastroprotection with acid suppressants
(proton pump inhibitors, PPIs, and histamine antagonists, H2As) was based mainly on the surrogate
measure of endoscopic ulcers. The limited information on damage to the bowel suggested that NSAID
plus PPI was more damaging than coxibs.
Eleven observational studies studied 1.6 million patients, of whom 911,000 were NSAID users, and showed
that 76% (range 65% to 90%) of patients with at least one gastrointestinal risk factor received no
prescription for gastroprotective agent with an NSAID. The exception was a cohort of US veterans with
previous gastrointestinal bleeding, where 75% had gastroprotection with an NSAID. When
gastroprotection was prescribed, it was often described as inadequate. A single study suggested that
patient adherence to prescribed gastroprotection was low.
Conclusion:  Evidence for efficacy of gastroprotection strategies with NSAIDs is limited. In clinical
practice few patients who need gastroprotection get it, and those who get it may not take it. For coxibs,
gastroprotection is inherent, although probably not complete.
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Background
Chronic pain affects one adult in five in Europe [1], limits
functioning, and is an enormous problem for healthcare.
Osteoarthritis, rheumatoid arthritis, and back pain have
the largest negative impact on quality of life of any
chronic condition (including cancer, chronic respiratory
conditions, or heart disease) for people living in the com-
munity [2].
NSAIDs are effective analgesic and anti-inflammatory
drugs that form the main pharmacological approach to
treating various forms of pain, and particularly chronic
musculoskeletal pain, but have a number of known
adverse effects. NSAIDs (and aspirin) are associated with
upper [3] and lower [4-6] gastrointestinal harm, acute
renal failure [7,8] and congestive heart failure [9,10]. Cox-
ibs are differentiated pharmacologically from traditional
NSAIDs by inhibiting only the cyclooxygenase-2 enzyme,
and clinically by lower rates of upper and lower gastroin-
testinal harm. All of these drugs (aspirin, NSAIDs, and
coxibs) may also be associated with increased risk of car-
diovascular harm, although increased cardiovascular
events are not generally seen for coxibs compared with
NSAIDs or placebo in studies in patients with arthritis.
Meta-analyses of large numbers of patients in trials of
individual coxibs [11] and all coxibs [12] found no sys-
tematic difference between coxib and NSAID. Meta-analy-
sis of recent observational studies with 3.5 million
patients showed that cardiovascular effects of some
NSAIDs (particularly diclofenac) were greater than some
coxibs [13]. Our views on rare but serious harm can be
directed by the amount of information available.
This paper concentrates on differences between NSAIDs
and coxibs for causing gastrointestinal harm. Possible
strategies for reducing gastrointestinal harm from NSAIDs
alone include use of coxib, NSAID plus PPI, NSAID plus
H2A, or NSAID plus misoprostol. Since misoprostol is
prescribed rarely in the UK [14] and elsewhere because of
other gastrointestinal adverse events it causes, the compet-
ing strategies for gastroprotection are use of histamine
antagonists or proton pump inhibitors with NSAID, or
coxib.
The effectiveness of any strategy is the product of efficacy
in clinical trials, and the usability of the strategy in clinical
practice. For drugs, this means that prescribing of a medi-
cine is appropriate, and that patients prescribed the med-
icine take it. Medicines not taken cannot be effective.
We examine each competing strategy in terms of available
evidence for reduction of gastrointestinal bleeding in clin-
ical studies and combine it with evidence from clinical
practice on whether the strategies work in the real world,
whether guidance on appropriate prescribing is followed,
and whether patients are able or willing to adhere to the
strategies over the longer term.
Methods
We searched for evidence from systematic reviews, ran-
domised trials and observational studies of clinical prac-
tice in several areas:
1. Evidence of reduction of upper and lower gastrointesti-
nal bleeding rates with coxibs compared with non-selec-
tive NSAIDs; in particular, evidence that results obtained
from clinical trials were also seen in clinical practice.
2. Evidence concerning levels of prescribing of gastropro-
tective strategies with non-selective NSAIDs to patients
with one or more risk factors for gastrointestinal bleeding,
and whether prescribing was described as appropriate
against any prescribing guidance.
3. Evidence concerning adherence to prescribed gastro-
protective strategies with non-selective NSAIDs.
A number of different search strategies were used to find
full publications of studies relating to these outcomes.
These were predominantly free-text searches of PubMed
and the Cochrane Library (to December 2005), bibliogra-
phies of papers and reviews, and discussions with experts.
Where evidence was available, we chose the highest level
available, preferably from good quality systematic reviews
and meta-analyses. The sensitivity of electronic databases
for observational studies is known not to be high [15,16],
so reviews and bibliographies were extensively searched
for references to studies of prescribing strategies in clinical
practice.
Any study that might have contributed was obtained in
full and read. For inclusion, the only criterion was that of
full publication; abstracts or posters were not accepted.
Formal quality scoring of included studies was not consid-
ered appropriate because of the likely mix of systematic
reviews, randomised trials, and observational studies. The
review was considered to be a descriptive narrative review,
without extensive pooling of data. No statistical methods
were planned, and none used.
Results
Reduction of upper gastrointestinal bleeding
Table 1 summarises evidence relating to the outcomes of
complicated upper gastrointestinal bleeding and/or
symptomatic ulcer from three large randomised trials
powered to detect these events (34,460 patients; [17-19]),
and six meta-analyses of randomised double blind trials
(52,474 patients in total, 44,415 of whom were not in one
of the large randomised trials; [20-25]). Some of the meta-
analyses include information from the large randomisedBMC Musculoskeletal Disorders 2006, 7:79 http://www.biomedcentral.com/1471-2474/7/79
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trials, with some inevitable, but limited, duplication. The
number of events was as low as 11 in one meta-analysis
[21] and as high as 283 in one large randomised trial [19].
Whether the outcome was complicated bleeding events,
symptomatic ulcers, or the combination, the rate with
coxibs was consistently about half that with NSAIDs. In
randomised trials, coxibs had significantly lower rates for
upper gastrointestinal bleeding, symptomatic ulcers,
endoscopic ulcers, anaemia, and withdrawal due to gas-
trointestinal symptoms (Table 2). For endoscopic ulcers,
benefits for coxib over NSAID were of the same absolute
magnitude (number needed to prevent 8) with or without
low dose aspirin [25].
Three large observational studies [26-28] with 3,093
bleeding events compared NSAIDs and coxibs in clinical
practice (Table 1). Each of these studies noted that
patients receiving coxibs had more gastrointestinal risk
factors than those receiving NSAIDs (channelling bias),
and adjusted risk estimates for this confounding. Each of
them used the outcome of hospital admission for gas-
trointestinal bleeding, usually upper gastrointestinal
bleeding. The number of events with particular treatments
could be low; only 17 admissions occurred with NSAID in
one [26], and only four with coxibs in another [27].
Despite the relative paucity of events, the risk of hospital
admission with coxib was about half that with NSAID.
Clinical practice produced the same magnitude of reduc-
tion for coxib compared with NSAID as did clinical trials.
Reduction of lower gastrointestinal bleeding
Lower gastrointestinal bleeding has not been extensively
studied. In the 1990s, using radioactive indium-labelled
white cells, it was shown that faecal excretion of white
cells (a marker of intestinal inflammation) was elevated
with oral NSAID. Calprotectin, a calcium binding protein
found in neutrophilic granulocytes, monocytes, and mac-
rophages, which resists faecal degradation was also used
as a marker. Use of the test in 312 patients taking NSAIDs
showed that 44% had raised faecal calprotectin concentra-
tions, much the same as estimates with indium studies
[29]. A retrospective analysis of a large (8,000 patient)
randomised trial comparing daily rofecoxib 50 mg with
naproxen 1000 mg used three markers for lower gastroin-
testinal bleeding (gross rectal bleeding with haemoglobin
decrease of 20 g/L or admission; haemoglobin decrease,
positive faecal blood, no upper gastrointestinal bleeding;
admission for lower perforation, obstruction, ulceration
or diverticulitis) [30]. It showed a significant reduction of
these events (by about 50%) with coxib compared with
NSAID, and that lower gastrointestinal bleeding was
about 40% of total (upper plus lower) gastrointestinal
bleeding events. A more recent randomised trial [6] com-
pared celecoxib 400 mg daily with placebo and naproxen
1000 mg plus omeprazole 20 mg daily, in 360 healthy
volunteers over two weeks. Capsule endoscopy found sig-
nificantly more small bowel mucosal breaks per patient
with celecoxib (0.3 breaks per patient on average) than
with placebo (0.1), but many more with naproxen plus
omeprazole (3.0).
Another marker of blood loss from the bowel may be
anaemia. Oral diclofenac 150 mg daily produced anaemia
in 10% of about 310 patients in 12 weeks [31]. Hooper et
al [24] noted a significantly lower rate of anaemia with
coxibs compared with NSAIDs (Table 2). A large meta-
analysis of celecoxib trials using clinical trial reports to
ascertain adverse events used two markers of anaemia, a
haemoglobin fall of ≥ 20 g/L, or a haematocrit fall of ≥ 5%
by the end of the study [25]. Celecoxib and placebo were
not significantly different, while rates with celecoxib were
always lower than those with NSAID, with numbers
needed to prevent one case of 92 and 18 for haemoglobin
and haematocrit respectively compared with NSAID.
NSAID plus PPI
Only three upper gastrointestinal bleeds were noted in a
meta-analysis of randomised trials using NSAID plus PPI
vs NSAID alone ([24]; Table 2), and only 18 symptomatic
ulcers. NSAIDs plus PPI had lower rates of endoscopic
ulcer and withdrawal due to gastrointestinal symptoms,
though with only 48 events for the latter calculation
(Table 2).
Two randomised trials [32,33] have directly compared
celecoxib 200 or 400 mg daily with NSAID plus PPI
(diclofenac 150 mg plus omeprazole 20 mg daily, or
naproxen 750 mg plus lanzoprazole 30 mg daily). Both
were conducted in patients with a previous ulcer bleed,
and who needed NSAID for arthritis. After ulcer healing,
patients were randomised to treatments over six months.
Serious gastrointestinal complications (bleeding events)
were no different for celecoxib than NSAID plus PPI
(4.2% vs 6.0%; relative risk 0.7, 95% confidence interval
0.3 to 1.5). There were similar rates of discontinuations
due to adverse events (4.5% vs 3.8%; relative risk 1.2, 0.5
to 2.8), but dyspepsia was significantly more common
with coxib than NSAID plus PPI (15% vs 7%; relative risk
2.1, 1.3 to 3.6).
Lower gastrointestinal mucosal breaks were more com-
mon with naproxen plus omeprazole than coxib or pla-
cebo [6]. Two observational studies using capsule
endoscopy also found high levels of small bowel injury
taking diclofenac 150 mg plus omeprazole 40 mg daily in
volunteers [34] and in patients with NSAID use for three
months or more plus some form of gastroprotection [35].B
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Table 1: Summary of gastrointestinal evidence of efficacy of coxibs
Reference Study design Population Main outcomes Main results Relative risk, coxib 
compared with 
NSAID (95% CI)
Large randomised trials
Bombardier et al. N Engl J Med 
2000 343: 1520–1528 [17]
Randomised trial powered for 
PUB outcome, comparing 50 mg 
rofecoxib with 1000 mg naproxen 
daily
Patients with RA, at least 50 years 
n = 8,076
Confirmed clinical upper GI 
events (perforation, bleeding 
symptomatic ulcer)
177 events, 53 complicated
Confirmed events at 2.1/100 pt years 
with rofecoxib, 4.5 with naproxen
Complicated 0.6 and 1.4 per 100 pt years
0.5 (0.3 to 0.6)
0.4 (0.2 to 0.8)
Silverstein et al. JAMA 2000 284: 
1247–1255 [18]
Randomised trial powered for 
PUB outcome, comparing 800 mg 
celecoxib with 2400 mg ibuprofen 
and 150 mg diclofenac daily
Patients with OA or RA, ≥ 18 
years n = 8,059
Confirmed upper GI ulcers and 
complication (bleeding, 
perforation, obstruction)
83 events including symptomatic ulcers, 
35 complicated
Confirmed events at 2.1/100 pt years 
with celecoxib, 3.5 with NSAID
Complicated at 0.8 and 1.5 per 100 pt 
years
0.6 (0.4 to 0.9)
0.5 (0.3 to 1.1)
Schnitzer et al. Lancet 2004 364: 
665–674 [19]
Randomised trial powered for 
PUB outcome, comparing 400 mg 
lumiracoxib with 2400 mg 
ibuprofen and 1000 mg naproxen 
daily
Patients with OA, at least 50 
years n = 18,325
Confirmed upper GI ulcers and 
complication (bleeding, 
perforation, obstruction)
283 events, 112 complicated
Confirmed events at 1.0% with 
lumiracoxib, 1.5% with NSAID
Complicated events at 0.3% with 
lumiracoxib, 0.9% with NSAID
0.7 (0.5 to 0.8)
0.3 (0.2 to 0.5)
Meta-analyses of randomised trials
Langman et al. JAMA 1999 282: 
1929–1933 [20]
Presecified meta-analysis of eight 
randomised trials of rofecoxib 
versus NSAIDs
OA patients, mean age 63 years n 
= 5,435
Confirmed clinical upper GI 
events (perforation, bleed, ulcer)
35 confirmed complicated events
Complicated events at 1.3/100 pt years 
with rofecoxib, 2.6 with NSAID
0.5 (0.3 to 1.0)
Goldstein et al. Am J 
Gastroenterol 2000 95: 1681–
1690 [21]
Meta-analysis of 14 randomised 
trials of celecoxib versus NSAIDs
OA or RA patients, mean age 60 
years n = 11,008
Confirmed clinical upper GI 
events (perforation, bleed, ulcer)
11 confirmed complicated events
Complicated events at 0.2/100 pt years 
with celecoxib, 1.7 with NSAID
0.2 (0.1 to 0.5)
Edwards et al. Pain 2004 111: 
286–296 [22]
Meta-analysis of nine randomised 
trials of valdecoxib versus 
NSAIDs
OA or RA patients, n = 5,726 Clinically significant upper GI 
bleed
10 confirmed complicated events
Complicated event rate 0.1% with 
valdecoxib, 0.4% with NSAID
0.2 (0.04 to 0.8)B
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Goldstein et al. Aliment 
Pharmacol Ther 2004 20: 527–
538 [23]
Meta-analysis of eight randomised 
trials of valdecoxib versus NSAID
OA or RA patients, mean age 58 
years n = 7,434
Confirmed clinical upper GI 
events (perforation, bleed, ulcer)
88 symptomatic ulcers, 19 complicated 
Symptomatic + complicated 0.8% with 
valdecoxib, 3.3% with NSAID
Complicated 0.2% with valdecoxib, 0.5% 
with NSAID
0.3 (0.2 to 0.4)
0.4 (0.1 to 0.9)
Hooper et al. BMJ 2004 329: 948–
952 [24]
Meta-analysis of 17 randomised 
trials of coxibs versus NSAIDs
n = 25,564 Variety of outcomes reported, 
including serious gastrointestinal 
complications, and symptomatic 
ulcers
114 serious gastrointestinal 
complications, 0.36% with coxib, 0.73% 
with NSAID
288 symptomatic ulcers, 0.8% with coxib, 
1.8% with NSAID
0.5 (0.4 to 0.8)
0.5 (0.4 to 0.6)
Moore et al. Arth Res Ther 2005 
7:R644–R655 [25]
Meta-analysis of 31 randomised 
trials of celecoxib versus NSAIDs
OA or RA n = 39,605 (31,171 in 
analysis of ulcers and bleeds)
Variety of outcomes reported 
including clinical ulcers and bleeds
184 clinical ulcers or bleeds, 0.4% with 
celecoxib, 0.9% with NSAID
0.6 (0.5 to 0.8)
Large observational studies
Mamdani et al. BMJ 2002 325: 
624–630 [26]
Observational cohort study Users of NSAID, coxib, or non 
users. Total population about 
144,000
Hospital admission for upper 
gastrointestinal bleeding
82 events with controls, 17 with NSAID, 
75 with coxib
Rofecoxib, but not celecoxib had 
significantly greater association with 
bleeding than controls
Celecoxib compared 
with NSAID 0.2 (0.1 to 
0.4)
Rofecoxib compared 
with NSAID 0.5 (0.3 to 
1.0)
MacDonald et al. Gut 2003 52: 
1265–1270 [27]
Retrospective cohort analysis Users of NSAID, coxibs, and non 
users. Total 26,000 incident cases 
of upper gastrointestinal 
haemorrhage
Hospital admission for upper 
gastrointestinal bleeding in high 
risk patients
2,875 events on NSAID, 4 on coxib 
Adjusted relative risk
0.4 (0.1 to 1.0)
Norgard et al. Aliment 
Pharmacol Ther 2004 19: 817–
825 [28]
Population based case-control 
study
Users of NSAID, coxibs, and 
non users. 780 incident cases in 
patients with high risk of 
gastrointestinal bleeding
Hospital admission for upper 
gastrointestinal bleeding
35 patients had been exposed to coxib 
(4.5%)
97 patients had been exposed to 
NSAID (12%)
Rofecoxib, but not celecoxib had 
significantly greater association with 
bleeding than controls
0.4 (0.3 to 0.5)
Table 1: Summary of gastrointestinal evidence of efficacy of coxibs (Continued)BMC Musculoskeletal Disorders 2006, 7:79 http://www.biomedcentral.com/1471-2474/7/79
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NSAID plus H2A
The only evidence for efficacy for histamine antagonists
with NSAID was for endoscopic ulcers (Table 2). There
was no evidence of efficacy for histamine antagonists pro-
tecting against lower bowel injury.
Appropriate prescribing
We found 11 studies related to the appropriateness of use
of gastroprotective strategies in patients using NSAIDs
[36-46] (Table 3). These studies included 1.56 million
patients, of whom 911,000 were recipients of NSAIDs.
Eight of the 11 studies reported that large proportions of
patients with gastrointestinal risk factors (including age ≥
65 years) were not receiving appropriate gastroprotection.
In what appeared to be mainly primary care populations,
non-use of gastroprotection in patients with at least one
gastrointestinal risk factor was about 73% to 90% in the
USA [37,44], 76% in Italy [38], 87% in Holland [39], 65%
in Canada [40], and 76% in the UK [45]. A study in sec-
ondary care in the UK found no gastroprotection in 76%
of patients with at least one gastrointestinal risk factor
[46], but gastroprotection non-use was lower at 25% in a
cohort of patients following a diagnosed ulcer or bleed
[41]. Pooling these 11 studies (Figure 1), 76% of the
patients with at least one gastrointestinal risk factor did
not receive a prescription for a gastroprotective agent.
Four of the 11 studies made some comment on the ade-
quacy or appropriateness of prescribing of NSAIDs and
coxibs, with or without gastroprotection. It was not
always clear what specific guidelines were used to judge
appropriateness, and results varied greatly. Two Dutch
studies [36,42] agreed on the adequacy of gastroprotec-
tion, at 55% and 65% respectively. Both defined inade-
quate prescribing as a lower dose H2A. In Canada
prescribing was deemed appropriate in 33% of patients
with no risk factors, and in 74% of those with at least one
risk factor [43]. By contrast, in UK secondary care only 8%
of NSAID users were deemed to have appropriate treat-
ment [46], and of those prescribed gastroprotection, 56%
were prescribed PPI, without comment on whether doses
of other gastroprotective agents were effective.
Three studies [36,43,45] commented on factors associated
with a higher propensity to be prescribed gastroprotec-
tion. Consistently mentioned were having two or more
risk factors, older age, and history of prior bleeding.
Three further studies [47-49] (Table 1) confirmed that gas-
troprotection was not used in about 80% of NSAID users,
while not providing information about risk factors.
Adherence
We could find only a single study examining adherence to
gastroprotection. Sturkenboom et al [36] followed 784
patients receiving PPI or H2A with NSAID. Half the users
of H2A had become non-adherent after about 100 days,
rising to about 70% by a year. Adherence was better with
PPI, but non-adherence was about 40% by a year, and had
risen to about 60% by the longest follow up of two years.
In a cohort of 711 subjects who stopped their NSAID and
who were followed up for up to two years [36], about 40%
had at least one additional prescription for acid suppress-
ing medicine after stopping NSAID, and somehat more
than 30% had at least two prescriptions.
Discussion
Current UK clinical guidance on NSAID use [50] includes
the following risk factors for developing an NSAID-
induced gastrointestinal adverse event.
• Age of 65 years and over.
￿ Previous history of gastroduodenal ulcer, gastrointesti-
nal bleeding, or gastroduodenal perforation.
￿ Concomitant use of medications that are known to
increase the likelihood of upper-gastrointestinal adverse
events (anticoagulants, aspirin, including low-dose aspi-
rin, and corticosteroids).
Table 2: Number of events on which overall conclusions about the efficacy of gastrointestinal protection strategies were based in a 
systematic review [24]
Number of events recorded
Outcome Coxib NSAID + PPI NSAID + H2A
Serious gastrointestinal complications 226 31
Symptomatic ulcers 452 18 1
Endoscopic ulcer 522 281 250
Anaemia 464 none 1
Withdrawal due to gastrointestinal symptoms 2171 48 57
Data from Hooper et al, 2004 [24]. The numbers show the actual numbers of events reported for each outcome in the paper, and the bold 
numbers indicate those where event rates were significantly lower with the strategy used than with NSAID aloneB
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Table 3: Summary of gastroprotection in clinical practice
Reference Study design Population Main outcomes Main results
Adherence and appropriateness of gastroprotection prescribing
Sturkenboom et al. Aliment 
Pharm Ther 2003 18: 1137–1147 
Holland [36]
Retrospective cohort study using 
primary care database between 
1997 and 2003
Patients aged ≥18 years with 12 
months data in database (382,000 
patients; 80,000 users of NSAIDs)
Adherence to gastroprotective 
agents
Of 65,190 patients taking NSAIDs, 784 had PPI or H2A, in about 
equal numbers. Patients prescribed gastroprotection were 
significantly older, had more risk factors, and had more 
cardiovascular disease
85% of H2A prescriptions were below recommended dose
31% of patients receiving PPI were non-adherent intially, but only 
about 40% took PPI long term
Appropriateness of gastroprotection prescribing
Smalley et al. Arthritis Rheum 
2002 46: 2195–2200 USA [37]
Retrospective cohort study using 
Medicaid database during 1999–
2000
Patients aged ≥ 50 years, with 12 
months data, filled one NSAID 
prescription (319,000, of whom 
107,000 received at least one 
NSAID prescription)
Frequency of use of 
gastroprotective measures 
according to NSAID use and risk 
factors
Recommended gastroprotection in 9% of patients with one risk 
factor, 11% of those with two risk factors. Most patients had no 
gastroprotection, whilst about 25% had inadequate 
gastroprotection.
No information about adherence
Pilotto et al. Drugs Aging 2003 
20:701–710 Italy [38]
Prospective study of drug use by 
patients aged ≥ 65 years. 3,200 
patients of 63 randomly chosen 
general practitioners, in 1999
Patients aged ≥ 65 years Of 3,200 
patients, 800 prescribed NSAID
Use of prescribed medicines NSAID and high-dose aspirin prescribed for 25% of patients
Use of GI protective drugs was 24% of NSAID users with at least 
one risk factor by virtue of age, slightly higher than for non users 
of NSAIDs
No information about adherence
Sturkenboom et al. Rheumatology 
2003 42 (Suppl 3):iii23–iii31 
Holland [39]
Retrospective cohort study using 
primary care database between 
1997 and 2002
Patients aged ≥18 years with 12 
months data in database (382,000 
patients; 80,000 users of NSAIDs)
Prevalence of prophylactic gastro-
protective strategies, and 
association with risk factors
In patients with at least one risk factor, 87% had no 
gastroprotective strategy
Proportion with no gastroprotection reduced over time
No information about adherence
Hartnell et al, Am J Geriatr 
Pharmacother 2004 2: 171–180 
Canada [40]
Retrospective cross-sectional 
study of pharmacy database for 
older people, 2001–2002
Patients aged ≥ 65 years with 12 
months data who filled 
prescription for NSAID, coxib, or 
high-dose aspirin (14,600 older 
patients using NSAID or coxib)
Use of gastroprotective strategies Of 11,000 NSAID users, 14% received gastroprotection Of 3,600 
coxib users, 5% received gastroprotection Gastroprotection not 
used in 65%
NSAID alone used in 67% of patients with only age as a risk factor, 
falling to 63% with one additional, and 52% with two additional 
risk factors
No information about adherence
Dominick et al. Ann 
Pharmacother 2004 38: 1159–
1164 USA [41]
Retrospective cohort study of 
sample of 4,338 veterans with GI 
bleeding in 1999
Patients had ICD code for GI 
ulceration or bleeding. Veterans 
were predominantly male, 50% 
aged 65 years or older
Use of gastroprotective strategies 
and prescribing NSAIDs in six 
months following event
1% prescribed coxib
20% prescribed NSAID; of these 75% prescribed 
gastroprotection, 25% no gastroprotection
No information about adherence
Herings & Goettsch. Ann 
Pharmacother 2004 38: 760–763 
Holland [42]
Nested case control analysis of 
database (1 million people; 10,000 
patients included), 2000 to 2001
Patients had to have at least two 
prescriptions for NSAID, with 
total duration > 100 days
Adequate gastroprotection (> 
400 μg misoprostol; ≥ 2 times 
recommended dose of H2A; ≥ 1 
times recommended dose of PPI)
One or more gastroprotective strategies used in 43% of NSAID 
users.
Of these 65% were adequate, and 35% inadequate Use of 
gastroprotection was linked to having 2 or more risk factors, 
history of ulcers, and older age
25% of NSAID users were also taking anticoagulants, 
corticosteroids, or low dose aspirin
No information about adherenceB
M
C
 
M
u
s
c
u
l
o
s
k
e
l
e
t
a
l
 
D
i
s
o
r
d
e
r
s
 
2
0
0
6
,
 
7
:
7
9
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
7
4
/
7
/
7
9
P
a
g
e
 
8
 
o
f
 
1
3
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Sebaldt et al. Am J Manag Care 
2004 10:742–750 Canada [43]
Cross-sectional study of 5,459 
patients of 119 physicians
Primary care physicians with hgih 
volume NSAID prescribing 
practices. OA patients had to be 
prescribed an NSAID
Adherence to appropriate 
prescribing of coxibs and 
NSAIDs, with or without 
gastroprotection
In patients with no GI risk factors (39% of total), 33% of 
prescribing was appropriate
In patients with at least one GI risk factor (61% of total), 74% of 
prescribing was appropriate
More use of coxibs with prior bleed, more severe pain, or with 
concomitant warfarin
Abraham et al. Gastroenterol 
2005 129: 1171–1178 USA [44]
Cross-sectional study of database, 
linked to other files (707,000 
NSAID users, 303,000 high risk 
patients), 2002
Various definitions of high 
gastrointestinal risk, including age 
≥ 65 years
Adherence to gastroprotection 
guidelines
43% of NSAID users were at high risk of GI complications
73% of these not prescribed gastroprotection
27% of these prescribed gastroprotection (18% NSAID plus PPI, 
9% coxib)
Greater gastroprotection use with two or more risk factors
Predictors of gastroprotection were previous upper 
gastrointestinal event, anticoagulant use, aspirin use, 
rheumatological disease
Thompson et al. Rheumatology 
2005 44:1308–1310 UK [45]
Cross-sectional survey of primary 
care practice 7,598 patients in 
practice in total
267 patients receiving repeat 
prescriptions for coxib or NSAID 
204 NSAID 63 coxib
Prescribing according to NICE 
guidance
69% NSAID users had one or more GI risk factors; antacids 
prescribed in 24% of those with a risk factor 74% coxib users had 
one or more GI risk factors; antacids prescribed in 6% of those 
with a risk factor
Price-Forbes et al. Rheumatology 
2005 44:921–924 UK [46]
Questionnaire survey of all 
patients attending clinics in 18 
rheumatology units over 2 weeks
2,846 patients, of whom 791 
were taking NSAIDs and 373 
coxibs. 65% of users had diagnosis 
of OA or RA
Prescribing according to GI risk 
factors
Of NSAID users, 92% had at least one GI risk factor (mostly 
prolonged use, and age ≥ 65 years); only 8% received appropriate 
treatment. Gastroprotective drug prescribed for 191 patients 
(24%), of which 56% were PPI
Of coxib users, 97% of prescribing was appropriate, with 77 (21%) 
taking gastroprotective drug
Pilotto et al. Aliment Pharmacol 
Ther 2005 22: 147–155 Italy [[47]
Prospective study of drug use by 
patients aged ≥ 65 years. 5,500 
patients of 133 general 
practitioners, in 2003
Patients aged ≥ 65 years Use of prescribed NSAIDs, and 
GI symptoms
NSAID use in 6%
Coxib use in 3%
New prescriptions for drugs for acid-related disorders in 13% of 
NSAID users, 6% of coxib users
No information on adherence
General information about gastroprotection prescribing
Schnitzer et al. Clin Ther 2001 23: 
1984–1998 USA [48]
Retrospective analysis of 
prescription database for 1998. 3 
million new users of NSAIDs
At least one NSAID prescription 
during 1998, and no use in prior 
120 days (< 30 days acute; > 30 
days chronic); 34% of chronic 
users 60 years or older
Use of gastroprotective 
medicines, by NSAID
In 1.4 million chronic users, the mean prescription was for 67 days 
supply.
Gastroprotection was prescribed for 14%, covering 22% of 
NSAID days
No information about risk factors or adherence
Teeling et al. Br J Clin Pharmacol 
2004 57: 337–343 Ireland [49]
Retrospective analysis of 
prescription database, 2000–2001 
(1.2 million people). About 
25,000 NSAID/coxib users
Patients aged 16 years or older 
prescribed an NSAID
Use of gastroprotective 
medicines, by NSAID
No gastroprotection in about 80%. PPI used in about 15%. Use of 
PPI higher with coxibs than with non-selective NSAIDs. Coxibs 
much more likely to be prescribed in over 65s. No information 
about risk factors or adherence
Pilotto et al. Aliment Pharmacol 
Ther 2005 22: 147–155 Italy [47]
Prospective study of drug use by 
patients aged ≥ 65 years. 5,500 
patients of 133 general 
practitioners, in 2003
Patients aged ≥ 65 years Use of prescribed NSAIDS, and 
GI symptoms
Non-selective NSAID use in 6%
Coxibs use in 3%
New prescriptions of drugs for acid-related disorders in 13% of 
NSAID users, 6% of coxib users
No information about adherence
Table 3: Summary of gastroprotection in clinical practice (Continued)BMC Musculoskeletal Disorders 2006, 7:79 http://www.biomedcentral.com/1471-2474/7/79
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￿ Presence of serious comorbidity, such as cardiovascular
disease, renal or hepatic impairment, diabetes, or hyper-
tension.
￿ Requirement for a prolonged duration of NSAID use.
￿ Use of the maximum recommended doses of NSAIDs.
￿ The presence of Helicobacter pylori infection.
￿ Excessive alcohol use.
￿ Heavy smoking.
Using these criteria, many NSAID users have a risk factor,
even if it is only age. A large US study found that 42% of
707,000 NSAID users were at higher risk [44], and in a
recent Italian study at least one risk factor was found in
68% of NSAID users [51]. Many different guidelines exist,
Scatter plot showing the percentage of patients with at least one gastrointestinal risk factor prescribed an NSAID plus gastro- protective agent (H2A or PPI) or a coxib Figure 1
Scatter plot showing the percentage of patients with at least one gastrointestinal risk factor prescribed an NSAID plus gastro-
protective agent (H2A or PPI) or a coxib. The size of the symbol is proportional to the size of the study.
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and they consistently recommend use of gastroprotective
agent (PPI or H2A) with NSAID, or use of coxib. All strat-
egies include interventions that should precede oral
NSAID use, such as lifestyle change, topical NSAIDs, para-
cetamol, and glucosamine; this study did not include any
of these, as they are not conventionally implicated in gas-
trointestinal damage.
This review set out to examine the strength of evidence on
particular gastroprotective strategies, whether guidance
about strategies was implemented by prescribers, and
whether patients were adherent to prescribed medicines.
The evidence available is mixed: some points are
addressed by large and coherent amounts of evidence,
while for others evidence is either lacking or limited. An
important limitation is that much of the information,
especially in observational studies in clinical practice,
does not differentiate between different NSAIDs or gastro-
protective agents. Moreover, while some evidence is of the
highest level from meta-analyses of high-quality ran-
domised trials [52], other evidence is from observational
studies, where testing of quality is more difficult. We do
know, however, that when criteria of quality, validity, and
size are met, observational studies produce similar results
to randomised trials [53].
The evidence on efficacy in reducing upper gastrointesti-
nal bleeding is considerable for coxibs. Three adequately-
powered randomised trials, and several meta-analyses of
large numbers of patients in randomised trials come to
the consistent conclusion that the rate of complicated
upper gastrointestinal events with coxibs is about half that
with NSAIDs. Rates of symptomatic ulcers, endoscopic
ulcers, and withdrawal because of gastrointestinal adverse
events were all about half with coxibs compared with
NSAIDs. For coxibs there is also evidence, from capsule
endoscopy studies, of reduced lower bowel damage com-
pared with NSAID plus PPI. Additionally, rates of anae-
mia were lower with coxibs than with NSAIDs in two large
meta-analyses [24,25], using several definitions of anae-
mia. This represents a large body of evidence, with many
events (Table 2), using clinical as well as surrogate out-
comes, and supported by large observational studies of
high quality.
Strategies of co-prescription of NSAID with either PPI or
H2A do not have this degree of evidence to support reduc-
tion of serious gastrointestinal complications. One reason
for is that this indication came considerably later than
original licensing of these gastroprotective agents and the
surrogate marker of endoscopic ulcers was used. Absence
of large outcome trials does not mean that they do not
work, and we have no direct comparisons of different
strategies in large numbers of patients with clinical events
as outcomes. Even combined, randomised trials of these
strategies had only four clinical events, and only the sur-
rogate marker of endoscopic ulcer supports efficacy.
Because we have two direct comparisons of coxib with
NSAID plus PPI in two randomised trials in high-risk
patients immediately after healing of a previous ulcer, and
with no statistically significant difference, we can proba-
bly assume at least some degree of upper gastrointestinal
protection with PPI use, although conclusions from these
trials may not apply to those without a previous ulcer. For
H2A, no such assumption is justified. We have evidence
from one large randomised trial and two cohort studies
that coxibs cause fewer problems in the lower bowel than
NSAID and PPI. Use of NSAID plus PPI, and especially
H2A, therefore fall some way short in terms of gastrointes-
tinal protection.
The evidence from observational studies is that most
patients at higher risk of gastrointestinal problems with
NSAIDs, by virtue of age or previous history, are not usu-
ally given gastroprotection. Most of the studies relate to
the period 2000–2002, and it may be that the introduc-
tion of better guidance since then has led to a change, but
we could not find evidence of that. Two further studies
published in 2006 confirm low use of gastroprotection in
patients with gastrointestinal risk factors taking NSAIDs.
One in primary care [54] reported a large uptake of coxibs
over 1998–2002, and low use of gastroprotection with
NSAIDs at any time over that period in patients aged 65
years or older. The second [55] surveyed prescribing by
Table 4: Summary of effectiveness
Strategy Efficacy Appropriate prescribing Adherence
Upper gastrointestinal injury
Coxib Extensive, robust evidence Low Effective
NSAID + PPI Surrogate only Low Low adherence
NSAID + H2A Surrogate only Low Low adherence
Lower gastrointestinal injury
Coxib Some evidence of efficacy Low Effective
NSAID + PPI Some evidence of lack of efficacy Low Low adherence
NSAID + H2A No evidence Low Low adherence
Summarised from Hooper et al, 2004 [24].BMC Musculoskeletal Disorders 2006, 7:79 http://www.biomedcentral.com/1471-2474/7/79
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rheumatology specialists in 2003/4, and found that even
in patients with four risk factors for gastrointestinal ulcer-
ation, gastroprotection was co-prescribed with NSAIDs in
no more than 40% of patients.
The evidence we have about prescribing is that guidance
has not generally been followed: three quarters of patients
with at least one gastrointestinal risk factor did not receive
a prescription for a gastroprotective agent. In individual
studies in primary care adherence prescribing guidelines
varied from 9% to 27% (Figure 1). It should be empha-
sised that this observational evidence is substantial, based
on almost 1.6 million patients, over 900,000 of whom
were prescribed NSAIDs, and studies often specifically
tested adherence to evidence-based guidelines (as in over
700,000 patients [44]).
Patient adherence to prescribed gastroprotection was
described in only one study [36], which found that adher-
ence to NSAID plus PPI or H2A declined rapidly, so that
after about six months the majority of patients were not
taking the gastroprotection prescribed. This is in accord
with many other studies of adherence to medicines.
Adherence to low dose aspirin was only 47% after a year
[56], was as low as 33% for statin and antihypertensive
medicines when prescribed together [57], and was even
about 20% with immunosuppressants following renal
transplantation [58]. Coxibs cause less gastrointestinal
harm, thus limiting or eliminating the need for co-pre-
scription and the problem of adherence.
We chose not to extend this review beyond the narrow
bound of gastroprotection, but other issues are important.
For instance, NSAID and coxib clinical trials have a range
of common adverse events [25]. Other serious adverse
events, like cardiovascular problems, have to be consid-
ered, and it seems increasingly likely that these will be
related to individual NSAIDs or coxibs rather than coxibs
versus NSAIDs [12,13]. Long-term acid suppression itself
may be associated with adverse events, including hip frac-
ture [59] and vertebral fracture [60]. Patient choice is an
increasingly important issue, and interestingly no experi-
enced patient with knee osteoarthritis chose conventional
NSAID therapy when presented with information about
common therapies [61].
In this review the use of observational studies to evaluate
adherence to clinical guidelines is not a limitation: the
observational studies report what is happening in clinical
practice. Moreover, many of these observational studies
were large and inclusive, minimising potential for bias.
Evidence from clinical trials (randomised, and control-
led) and clinical practice (observational studies) tend to
be similar when criteria of quality, validity and size are
met [60]. It is seen for cardiovascular effects of coxibs and
NSAIDs in meta-analyses of clinical trials [12] and obser-
vational studies [13].
For a strategy to be effective, it has to translate efficacy
from clinical trials to clinical practice. With NSAIDs, but
not coxibs, gastrointestinal protection can be delivered
only if those patients who need gastroprotection are given
it, and those who are given gastroprotection take it. Effec-
tiveness evidence is summarised for the different strategies
is in Table 4. The evidence for efficacy of co-prescription
of gastroprotective agents in protecting the upper gas-
trointestinal tract is largely limited to the surrogate meas-
ure of endoscopic ulcers, though it is probable that
bleeding events would be reduced. Such evidence we have
suggests that PPIs have no efficacy in protecting the small
bowel. From clinical practice, the evidence is that those
patients who need gastroprotection do not get it, while
those who get it do not take it. As a strategy, this is a con-
siderable way short of ideal.
Conclusion
There is considerable evidence that patients who need gas-
troprotection because they have at least one gastrointesti-
nal risk factor do not get it, despite clear guidelines
suggesting that they should. There is limited evidence that
those who get gastroprotection in the form of PPI or H2A
do not take it. As a strategy, this is a considerable way
short of ideal.
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